Temozolomide as first-line agent in treating high-grade gliomas: Phase II study

Journal of Neuro-Oncology

Volumn 67, Issue 1-2, 2004, Pages 77-81

  Chibbaro, Salvatore ^a,c   Benvenuti, L ^a   Caprio, A ^a   Carnesecchi, S ^a   Pulera F ^a   Faggionato, F ^a   Serino, D ^a   Galli, C ^a   Andreuccetti, M ^a   Buxton, N ^b   Gagliardi, R ^a  

^a Livorno Hospital   (Italy)

^b WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c NONE   (Italy)

Author keywords

Chemotherapy; Malignant gliomas; Temozolomide

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; ONDANSETRON; STEROID; TEMOZOLOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG CHOICE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MUSCLE WEAKNESS; NAUSEA; OLIGODENDROGLIOMA; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 12144286418     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000021728.36747.93     Document Type: Article

References (38)

1. Schold SC Jr, Kuhn JG, Chang SM, Bosik ME, Robins HI, Mehta MP, Spence AM, Fulton D, Fink KL, Prados MD: A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. Neuro-oncology 2: 34-39, 2000
2. Huncharek M, Muscat J: Treatment of recurrent high-grade astrocytoma: results of a systematic review of 1415 patients. Anticancer Res 18: 1303-1311, 1998
3. Abrey LE, Christodoulou C: Temozolomide for treating brain metastases. Semin Oncol 28(4 suppl 13): 34-42, 2001
4. Harris MT, Rosenthal MA, Ashley DL, Cher L: An Australian experience with temozolomide for the treatment of recurrent high grade gliomas. J Clin Neurosci 8: 325-327, 2001
5. Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, Karabelis A, Bacoyiannis C, Skarlos DV: Phase II study of temozolomide in heavily pre-treated cancer patients with brain metastases. Ann Oncol 12: 249-254, 2001
6. Newton HB: Novel chemotherapeutic agents for the treatment of brain cancer. Expert Opin Investig Drugs 9: 2815-2829, 2000
7. Brandes AA, Pasetto LM, Monfardini S: New drugs in recurrent high grade gliomas. Anticancer Res 20: 1913-1920, 2000
8. Friedman HS: Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin Oncol 27(3 suppl 6): 35-40, 2000
9. van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ: Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47: 779-784, 2000
10. Agarwala SS, Kirkwood JM: Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5: 144-151, 2000
11. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81: 1022-1030, 1999
12. Burton E, Prados M: New chemotherapy options for the treatment of malignant gliomas. Curr Opin Oncol 11: 157-161, 1999
13. Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, Lejeune F: Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol 42: 433-440, 1998
14. Van Den Bent MJ, Keime-Guibert F, Brandes AA, Taphoorn MJB, Kros JM, Eskens FALM, Carpentier AF: Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 57: 340-342, 2001
15. Brandes AA, Ermani M, Basso U, Amista P, Berti F, Scienza R, Rotilio A, Pinna G, Gardinian M, Monfardini S: Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol 12: 255-257, 2001
16. Friedman HS, Kerby T, Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res 6: 2585-2597, 2000
17. Yung WK: Temozolomide in malignant gliomas. Semin Oncol 27(3 suppl 6): 27-34, 2000
18. Osoba D, Brada M, Yung WK, Prados M: Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18: 1481-1491, 2000
19. Miller JL: Oral temozolomide approved for refractory brain tumor. Am J Health Syst Pharm 56: 1910, 1999
20. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, Colquhoun I, Lewis P, Brampton MH: Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484-488, 1997
21. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12: 259-266, 2001
22. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Seller RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000
23. Prados MD: Future directions in the treatment of malignant gliomas with temozolomide. Semin Oncol 27(3 suppl 6): 41-46, 2000
24. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762-2771, 1999
25. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989
26. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 56: 1106-1111, 1990
27. Dinnes J, Cave C, Huang S, Major K, Milne R: The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review. Health Technol Assess 5: 1-73, 2001
28. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19: 2449-2455, 2001
29. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58: 4363-4367, 1998
30. Stupp R: Daily temozolomide and concomitant radiotherapy followed by adjuvant temozolomide for newly diagnosed glioblastoma multiforme. A well tolerated and promising regimen. Proc ASCO 18: 1999
31. Hosli P, Sappino AP, De Tribolet N, Dietrich PY: Malignant glioma: should chemotherapy be overthrown by experimental treatments? Ann Oncol 9: 589-600, 1998
32. Pech IV, Peterson K, Cairncross JG: Chemotherapy for brain tumour. Oncology 12: 537-543, 1998
33. Chamberlain MC, Kormanik P: Salvage chemotherapy with taxol for recurrent anplastic astrocytomas. J Neuro-Oncol 43: 71-78, 1999
34. Brandes AA: Procarbazine and high-dose tamoxifen as second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol 17: 645-650, 1999
35. Friedman HS: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516-1525, 1999
36. Tseng SH, Bobola MS, Berger MS, Silber JR: Characterization of paclitaxel (Taxol) sensitivity in human glioma-and medulloblastoma-derived cell lines. Neuro-oncology 1: 101-108, 1999
37. Nieder C, Grosu AL, Molls M: A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26: 397-409, 2000
38. Stupp R, Gander M, Leyvraz S, Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 12: 552-560, 2001